PROTAGONIST THERAPEUTICS, INC. (PTGX) FY2026 Q2 P&L / Income Statement

PROTAGONIST THERAPEUTICS, INC. (PTGX) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. Consolidated revenue, costs and expenses.

License and collaboration revenue

213,475,000 US dollars

Total operating expenses

54,709,000 US dollars

Income (loss) from operations

158,766,000 US dollars

Other income (expense), net (calculated)

6,348,000 US dollars

Income (loss) before income tax expense

165,114,000 US dollars

Income tax expense

2,265,000 US dollars

Net income (loss)

162,849,000 US dollars

Undisclosed sources

213,475,000 US dollars. The filing reports revenue as one line and discloses no sources of it.

Total operating expenses

54,709,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.